Peter Buontempo

519 total citations
16 papers, 366 citations indexed

About

Peter Buontempo is a scholar working on Infectious Diseases, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Peter Buontempo has authored 16 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 7 papers in Molecular Biology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Peter Buontempo's work include Viral Infections and Immunology Research (5 papers), HIV Research and Treatment (4 papers) and Viral gastroenteritis research and epidemiology (4 papers). Peter Buontempo is often cited by papers focused on Viral Infections and Immunology Research (5 papers), HIV Research and Treatment (4 papers) and Viral gastroenteritis research and epidemiology (4 papers). Peter Buontempo collaborates with scholars based in United States, United Kingdom and Australia. Peter Buontempo's co-authors include Juliette O’Connell, Stuart Cox, Viyyoor Girijavallabhan, Edward J. Rozhon, Angela Skelton, John A. Howe, Robert A. Ogert, Robert Ralston, Lei Ba and Julie Strizki and has published in prestigious journals such as Blood, Journal of Virology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Peter Buontempo

15 papers receiving 355 citations

Peers

Countries citing papers authored by Peter Buontempo

Since Specialization

Citations

This map shows the geographic impact of Peter Buontempo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Buontempo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Buontempo more than expected).

Fields of papers citing papers by Peter Buontempo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Buontempo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Buontempo. The network helps show where Peter Buontempo may publish in the future.

Co-authorship network of co-authors of Peter Buontempo

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Buontempo. A scholar is included among the top collaborators of Peter Buontempo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Buontempo. Peter Buontempo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model 2020 ·Frontiers in Immunology ·Timothy W. Phares, Vinayaka Kotraiah, Deshapriya S. Karunarathne, Jing Huang, Cecille D. Browne, Peter Buontempo, Marc Mansour, Amy R. Noe, Michelle Wykes, (unknown), Moriya Tsuji, Gabriel M. Gutierrez	7
2	A Peptide-Based Checkpoint Immunomodulator Alleviates Immune Dysfunction in Murine Polymicrobial Sepsis 2020 ·Shock ·Timothy W. Phares, Vinayaka Kotraiah, Chun‐Shiang Chung, Jacqueline Unsinger, Monty B. Mazer, Kenneth E. Remy, Cecille D. Browne, Peter Buontempo, Marc Mansour, (unknown), Alfred Ayala, Richard S. Hotchkiss, Gabriel M. Gutierrez	15
3	Microvascular and systemic responses to novel PEGylated carboxyhaemoglobin-based oxygen carrier in a rat model of vaso-occlusive crisis 2019 ·Artificial Cells Nanomedicine and Biotechnology ·William H. Nugent, Ronald Jubin, Peter Buontempo, (unknown), (unknown)	5
4	Pegylated Carboxyhemoglobin Bovine (SANGUINATE®) Restores RBCs Roundness and Reduces Pain during a Sickle Cell Vaso-Occlusive Crisis 2017 ·Blood ·Peter Buontempo, Ronald Jubin, (unknown), (unknown), (unknown), Siobhán O’Brien, (unknown), Abraham Abuchowski	3
5	Imaging-Based Assay for Identification and Characterization of Inhibitors of CXCR4-Tropic HIV-1 Envelope-Dependent Cell-Cell Fusion 2011 ·SLAS DISCOVERY ·Susanne Krämer, Peter Buontempo, Sony Agrawal, Robert Ralston	3
6	Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor 2009 ·Virology ·Peter Buontempo, Lisa Wojcik, (unknown), Robert A. Ogert, Julie Strizki, John A. Howe, Robert Ralston	4
7	Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist Vicriviroc 2009 ·Journal of Virology ·Robert A. Ogert, Lei Ba, Yan Hou, (unknown), Ping Qiu, José S. Duca, Nicholas Murgolo, Peter Buontempo, Robert Ralston, John A. Howe	31
8	Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120 2008 ·Virology ·Robert A. Ogert, Lisa Wojcik, (unknown), Lei Ba, Peter Buontempo, Robert Ralston, Julie Strizki, John A. Howe	72
9	Antiviral Activity of Transiently Expressed IFN-κ Is Cell-Associated 2006 ·Journal of Interferon & Cytokine Research ·Peter Buontempo, Ronald Jubin, (unknown), Nicole Wagner, Gregory R. Reyes, Bahige M. Baroudy	17
10	Primary Human Hepatocyte Culture for the Study of HCV 2003 ·Humana Press eBooks ·Juliette O’Connell, Stuart Cox, Peter Buontempo, Angela Skelton, Liubomir A. Pisarov, Kenneth Dorko, Stephen C. Strom	1
11	SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2 1997 ·Antiviral Research ·(unknown), Robert A. Chase, (unknown), (unknown), Eric Ferrari, Angela Skelton, Peter Buontempo, Stuart Cox, (unknown), Jacquelyn Wright-Minogue, (unknown), Joseph Kelly, (unknown), Ann D. Kwong, (unknown), Juliette O’Connell	27
12	SCH 48973: a potent, broad-spectrum, antienterovirus compound 1997 ·Antimicrobial Agents and Chemotherapy ·Peter Buontempo, Stuart Cox, Jacquelyn Wright-Minogue, (unknown), Angela Skelton, Eric Ferrari, (unknown), Edward J. Rozhon, Viyyoor Girijavallabhan, John F. Modlin, Juliette O’Connell	45
13	Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of the three poliovirus serotypes 1997 ·Structure ·(unknown), Allen Smith, (unknown), Stuart Cox, Peter Buontempo, Angela Skelton, (unknown), Edward J. Rozhon, Jerome Schwartz, Viyyoor Girijavallabhan, Juliette O’Connell, Eddy Arnold	85
14	Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies 1996 ·Antiviral Research ·Stuart Cox, Peter Buontempo, Jacquelyn Wright-Minogue, (unknown), Angela Skelton, Eric Ferrari, Jerome Schwartz, Edward J. Rozhon, (unknown), Viyyoor Girijavallabhan, Juliette O’Connell	22
15	Mechanism of action of SCH 47802, an antipicornavirus molecule 1995 ·Antiviral Research ·Peter Buontempo, Jacquelyn Wright-Minogue, (unknown), (unknown), (unknown), Edward J. Rozhon, J. Schwartz, Juliette O’Connell	1
16	SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating 1993 ·Antiviral Research ·Edward J. Rozhon, Stuart Cox, Peter Buontempo, Juliette O’Connell, (unknown), (unknown), J Schwartz, George Miller, Eddy Arnold, (unknown), Casey D. Morrow, Sandra A. Jablonski, (unknown), (unknown), (unknown), Viyyoor Girijavallabhan	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact